Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rushab Choksi

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Review of Cardiovascular Therapy|November 9, 2011
Less RAAS is more, or notNiren K Shah, Rushab Choksi, Benjamin J Epstein
Expert Review of Cardiovascular Therapy|November 11, 2009
Recent changes in the landscape of combination RAS blockadeBenjamin J Epstein, Steven M Smith, Rushab Choksi
Pharmacotherapy|March 7, 2012
Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitusNiren K Shah, Wasim E Deeb, Rushab Choksi, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 19, 2013
SGLT-2 inhibitors and their potential in the treatment of diabetesRebecca F Rosenwasser, Senan Sultan, David Sutton, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 6, 2021
A Critical Review of the Efficacy and Safety of InclisiranJennifer Hardy, Stephanie Niman, Edward Pereira, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 7, 2021
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering AgentJennifer Hardy, Stephanie Niman, Rebecca F Goldfaden, et al.
Drugs in R&D|March 27, 2021
A Review on the Efficacy and Safety of Oral SemaglutideStephanie Niman, Jennifer Hardy, Rebecca F Goldfaden, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 11, 2021
Correction to: A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering AgentJennifer Hardy, Stephanie Niman, Rebecca F Goldfaden, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Review of Cardiovascular Therapy|November 9, 2011
Less RAAS is more, or notNiren K Shah, Rushab Choksi, Benjamin J Epstein
Expert Review of Cardiovascular Therapy|November 11, 2009
Recent changes in the landscape of combination RAS blockadeBenjamin J Epstein, Steven M Smith, Rushab Choksi
Pharmacotherapy|March 7, 2012
Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitusNiren K Shah, Wasim E Deeb, Rushab Choksi, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 19, 2013
SGLT-2 inhibitors and their potential in the treatment of diabetesRebecca F Rosenwasser, Senan Sultan, David Sutton, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|May 6, 2021
A Critical Review of the Efficacy and Safety of InclisiranJennifer Hardy, Stephanie Niman, Edward Pereira, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 7, 2021
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering AgentJennifer Hardy, Stephanie Niman, Rebecca F Goldfaden, et al.
Drugs in R&D|March 27, 2021
A Review on the Efficacy and Safety of Oral SemaglutideStephanie Niman, Jennifer Hardy, Rebecca F Goldfaden, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 11, 2021
Correction to: A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering AgentJennifer Hardy, Stephanie Niman, Rebecca F Goldfaden, et al.
Pageof 1